SMPD1 and AL amyloidosis: Treating human multiple myeloma U266 cells with EGCG resulted in plasma membrane lipid raft disruption via the 67-LR/acid sphingomyelinase (ASM) pathway and the elicitation of EGCG-induced cell death.